Canadian Cancer Trials Group Bulletins

Finance and Operations


Trials Closed to Accrual

Canadian Cancer Trials Group LY.12 -- A Phase III Study of Gemcitabine, Dexamethasone and Cisplatin Compared to Dexamethasone, Cytarabine and Cisplatin +/- Rituximab [(R)GDP VS (R)-DHAP] as Salvage Chemotherapy for Patients with Relapsed or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior to Autologous Stem Cell Transplant and Followed by Maintenance Rituximab Versus Observation

Randomization to randomization #1 was closed to accrual November 9, 2011.
Randomization #2 to maintenance therapy will still continue.

________________________________________

Canadian Cancer Trials Group HN.6 -- A Phase III Study of Standard Fractionation Radiotherapy with Concurrent High-Dose Cisplatin versus Accelerated Fractionation Radiotherapy with Panitumumab in Patients with Locally Advanced Stage III and IV Squamous Cell Carcinoma of the Head and Neck

Canadian Cancer Trials Group HN.6 reached its target accrual and was closed to accrual November 7, 2011.

________________________________________

Canadian Cancer Trials Group IND.195 -- A Phase II Study of SB939 in Patients with Recurrent or Metastatic Castration Resistant Prostate Cancer

Canadian Cancer Trials Group IND.195 was closed to accrual November 4, 2011.

Thank you to all participating centres, staff and patients for their support of these trials.